Unscrambling the Role of Redox-Active Biometals in Dopaminergic Neuronal Death and Promising Metal Chelation-Based Therapy for Parkinson's Disease

Int J Mol Sci. 2023 Jan 9;24(2):1256. doi: 10.3390/ijms24021256.

Abstract

Biometals are all metal ions that are essential for all living organisms. About 40% of all enzymes with known structures require biometals to function correctly. The main target of damage by biometals is the central nervous system (CNS). Biometal dysregulation (metal deficiency or overload) is related to pathological processes. Chronic occupational and environmental exposure to biometals, including iron and copper, is related to an increased risk of developing Parkinson's disease (PD). Indeed, biometals have been shown to induce a dopaminergic neuronal loss in the substantia nigra. Although the etiology of PD is still unknown, oxidative stress dysregulation, mitochondrial dysfunction, and inhibition of both the ubiquitin-proteasome system (UPS) and autophagy are related to dopaminergic neuronal death. Herein, we addressed the involvement of redox-active biometals, iron, and copper, as oxidative stress and neuronal death inducers, as well as the current metal chelation-based therapy in PD.

Keywords: Parkinson’s disease; biometals; chelation; copper; iron; redox-active.

Publication types

  • Review

MeSH terms

  • Chelating Agents / pharmacology
  • Chelating Agents / therapeutic use
  • Copper
  • Dopaminergic Neurons / pathology
  • Humans
  • Iron
  • Metals
  • Oxidation-Reduction
  • Oxidative Stress
  • Parkinson Disease* / pathology
  • Trace Elements*

Substances

  • Trace Elements
  • Copper
  • Metals
  • Iron
  • Chelating Agents